表面活性蛋白（Surfactant）

廣州健侖生物科技有限公司

肺部表面活性蛋白是一種由Ⅱ型肺泡細(xì)胞分泌的磷脂和蛋白組成的復(fù)合物，可在肺泡氣液界面降低表面張力，提供肺泡穩(wěn)定所需的正?？諝饬魍?。從肺部表面蛋白復(fù)合物中分離出來的4種蛋白A,B,C和D。 SP-A(28-36kDa)和SP-D(43kDa)都是膠原醣類結(jié)合蛋白，而SP-B(8-9kDa)和SP-C(4kDa)是非膠原的疏水蛋白。SP-B會在肺腺癌中腺泡、乳頭狀突起、細(xì)支氣管肺泡穩(wěn)定增長表達(dá)。肺鱗癌、大細(xì)胞肺癌和非肺腺癌都不表達(dá)SP-B。因此此抗體在肺腺癌的研究中有意義。

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

表面活性蛋白（Surfactant）

【產(chǎn)品介紹】

細(xì)胞定位：細(xì)胞漿

克隆號：1B9

同型：IgG

適用組織：石蠟/冰凍

陽性對照：肺腺癌

抗原修復(fù)：熱修復(fù)（EDTA）

抗體孵育時間：60min

想了解更多的產(chǎn)品及服務(wù)請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

由中科院上海生命科學(xué)院/上海交大醫(yī)學(xué)院健康科學(xué)研究所金穎教授帶隊的關(guān)于“基于誘導(dǎo)多能干細(xì)胞技術(shù)的若干重大疾病模型與機(jī)理研究”的“973”科技部重大科學(xué)研究項目，就是希望能找到誘導(dǎo)iPS細(xì)胞的方法。
研究團(tuán)隊首先建立了從尿液細(xì)胞、羊水細(xì)胞誘導(dǎo)iPS的技術(shù)平臺，中國醫(yī)學(xué)科學(xué)院血液學(xué)研究所程濤教授研究組建立了外周血細(xì)胞無基因插入的episomal方法誘導(dǎo)iPS的技術(shù)平臺，北京大學(xué)鄧宏魁教授研究組在世界上*在小鼠建立了*利用小分析化合物誘導(dǎo)iPS的技術(shù)平臺。這些技術(shù)使得建立人誘導(dǎo)全能干細(xì)胞更方便、更安全，為今后的臨床應(yīng)用打下了重要基礎(chǔ)。
同時，課題組建立了多個的疾病ips細(xì)胞模型，如帕金森氏疾病、老年癡呆癥、血友病及白血病等疾病iPS細(xì)胞模型，并進(jìn)行了疾病發(fā)生發(fā)展的研究，為今后的細(xì)胞治療、基因治療提供了可靠的科學(xué)依據(jù)。例如，課題組在小鼠上做了初步嘗試，iPS細(xì)胞可以成功分化為視網(wǎng)膜底干細(xì)胞，并且移植獲得成功。血友病的基因矯正實(shí)驗(yàn)研究也正在血研所開展。

Pulmonary surfactant protein is a complex of phospholipids and proteins secreted by type II alveolar cells, which reduces surface tension at the alveolar gas-liquid interface and provides the normal air circulation required for stabilization of the alveoli. Four proteins A, B, C and D isolated from the pulmonary surface protein complex. Both SP-A (28-36 kDa) and SP-D (43 kDa) are collagen-carbohydrate binding proteins whereas SP-B (8-9 kDa) and SP-C (4 kDa) are non-collagenous hydrophobins. SP-B lung adenocarcinoma in the acinar, papillary, bronchial alveolar expression of stable growth. Lung squamous cell carcinoma, large cell lung cancer and non-lung adenocarcinoma do not express SP-B. Therefore, this antibody is of great significance in the study of lung adenocarcinoma.

"973" major scientific research project of Ministry of Science and Technology led by Professor Jin Ying of Shanghai Institutes for Biological Sciences / Shanghai Jiaotong University School of Medicine and Institute of Health Sciences, Chinese Academy of Sciences on the "Research on Several Major Disease Models and Mechanisms Based on Induced Pluripotent Stem Cell Technology" Find ways to induce iPS cells.
The research team first established a technology platform for inducing iPS from urine cells and amniotic fluid cells. The research team of professor Cheng Tao of Institute of Hematology, Chinese Academy of Medical Sciences established a technology platform for induction of iPS by episomal method of peripheral blood cell gene-free insertion. Professor Deng Hongkui of Peking University The research team is the first in the world to set up a technology platform for fully utilizing small analytical compounds to induce iPS in mice. These techniques make it more convenient and safer to establish human-induced totipotent stem cells and lay an important foundation for future clinical applications.
At the same time, the research group established a number of ips cell models of diseases, such as Parkinson's disease, Alzheimer's disease, hemophilia and leukemia and other diseases iPS cell model, and carried out the development of disease research for future cell therapy, Gene therapy provides a reliable scientific basis. For example, the group made a preliminary attempt in mice, iPS cells can be successfully differentiated into stem cells of the retina, and the transplant was successful. Hemophilia gene correction experiments are also carried out by the Institute of Blood.